7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
1. A method of treating non-alcoholic fatty liver disease (NAFLD), the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising 7-hydroxy-cannabidiol (7-OH-CBD):
and a pharmaceutically acceptable carrier.
2. The method as claimed in claim 1 , wherein the treatment involves lowering triglyceride levels.
3. The method as claimed in claim 2 , wherein the high triglyceride levels are caused by obesity.
4. The method as claimed in claim 2 , wherein the high triglyceride levels are caused by type II diabetes.
5. The method as claimed in claim 2 , wherein the high triglyceride levels are caused by medication.
6. The method as claimed in claim 1 , wherein the dose of 7-OH-CBD is between 1 and 1000 mg/kg day.
7. The method as claimed in claim 1 , wherein the 7-OH-CBD is used in combination with another medicament, wherein the 7-OH-CBD may be formulated for administration separately, sequentially or simultaneously with the other medicament or the combination may be provided in a single dosage form.
8. The method as claimed in claim 1 , wherein the 7-OH-CBD is in a pure, isolated or synthetic form.